Search for appropriate treatment strategy using fulvestrant for postmenopausal ER-positive advanced or recurrent breast cancer patients in Japan (JBCRG-C06; Safari)

被引：0

作者：

Kawaguchi, H. ^{[1
,11
]}

Masuda, N. ^{[2
]}

Nakayama, T. ^{[3
]}

Aogi, K. ^{[4
]}

Anan, K. ^{[5
]}

Ito, Y. ^{[6
]}

Ohtani, S. ^{[7
]}

Sato, N. ^{[8
]}

Saji, S. ^{[9
]}

Tokunaga, E. ^{[10
]}

Nakamura, S.

Hasegawa, Y. ^{[12
]}

Hattori, M. ^{[13
]}

Fujisawa, T. ^{[14
]}

Morita, S. ^{[15
]}

Yamaguchi, M. ^{[16
]}

Yamashita, T. ^{[17
]}

Yamamoto, Y. ^{[18
]}

Ohno, S. ^{[19
]}

Toi, M. ^{[20
]}

机构：

[1] Matsuyama Red Cross Hosp, Breast Surg, Matsuyama, Ehime, Japan

[2] Osaka Natl Hosp, Dept Surg Breast Oncol, Osaka, Japan

[3] Osaka Med Ctr Canc & Cardiovasc Dis, Dept Breast & Endocrine Surg, Osaka, Japan

[4] Shikoku Canc Ctr, Dept Breast Oncol, Matsuyama, Ehime, Japan

[5] Kitakyushu Municipal Med Ctr, Dept Surg, Kitakyushu, Fukuoka, Japan

[6] Canc Inst Hosp JFCR, Breast Med Oncol Dept, Tokyo, Japan

[7] Hiroshima City Hiroshima Citizens Hosp, Dept Breast Surg Hiroshima, Hiroshima, Japan

[8] Niigata Canc Ctr Hosp, Dept Breast Oncol, Niigata, Japan

[9] Fukushima Med Univ, Dept Med Oncol, Fukushima, Japan

[10] Kyushu Canc Ctr, Dept Breast Oncol, Fukuoka, Japan

[11] Showa Univ, Sch Med, Showa Univ Hosp, Dept Surg,Div Breast Surg Oncol, Tokyo 142, Japan

[12] Hirosaki Municipal Hosp, Dept Breast Surg, Hirosaki, Aomori, Japan

[13] Aichi Canc Ctr Hosp, Dept Breast Oncol, Nagoya, Aichi 464, Japan

[14] Gunma Prefectural Canc Ctr, Dept Breast Oncol, Ohta, Gunma, Japan

[15] Kyoto Univ, Dept Biomed Stat & Bioinformat, Grad Sch Med, Kyoto, Japan

[16] JCHO Kurume Gen Hosp, Dept Breast Surg, Kurume, Fukuoka, Japan

[17] Komagome Hosp, Dept Breast Surg, Tokyo Metropolitan Canc & Infect Dis Ctr, Tokyo, Japan

[18] Kumamoto Univ, Grad Sch Med Sci, Dept Breast & Endocrine Surg, Kumamoto, Japan

[19] Canc Inst Hosp JFCR, Breast Oncol Ctr, Tokyo, Japan

[20] Kyoto Univ, Dept Breast Surg, Grad Sch Med, Kyoto, Japan

来源：

EUROPEAN JOURNAL OF CANCER | 2016年 / 57卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

379

引用

页码：S109 / S109

页数：1

共 48 条

[21] Real-world efficacy and safety of palbociclib combined with fulvestrant in japanese patients with ER-positive HER2-negative advanced or metastatic breast cancer
Seki, Hirohito
Sakurai, Takashi
Maeda, Yuka
Oki, Naohiko
Aoyama, Mina
Yamaguchi, Ryou
Shimizu, Ken
Higeta, Kaori
CANCER RESEARCH, 2020, 80 (04)
[22] Efficacy of fulvestrant 500 mg in Japanese postmenopausal advanced/recurrent breast cancer patients and factors associated with prolonged time-to-treatment failure
Araki, Kazuhiro
Ishida, Naoko
Horii, Rie
Takahashi, Shunji
Akiyama, Futoshi
Ito, Yoshinori
Ohno, Shinji
EXPERT OPINION ON PHARMACOTHERAPY, 2015, 16 (17) : 2561 - 2568
[23] Omission of axillary surgery in cN0, postmenopausal ER-positive/HER2-negative breast cancer patients undergoing breast-conserving treatment
Kwon, Yeonjoo
Lim, Jihe
Ha, Boram
Kim, Sanghwa
Park, Jung Ho
Lim, Young Ah
Kang, Hee-Joon
Kim, Doyil
Lee, Janghee
GLAND SURGERY, 2024, 13 (08)
[24] A phase I study of RAD1901, an oral selective estrogen receptor degrader, in ER-positive, HER2-negative, postmenopausal advanced breast cancer patients.
Harb, Wael A.
Garner, Fiona
Clarkin, Marcie
Roberge, Kathleen A.
Harris, Alan G.
Williams, Gregory
Hattersley, Gary
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[25] Efficacy of fulvestrant 500 mg in Japanese postmenopausal advanced/recurrent breast cancer patients and factors associated with prolonged time-to-treatment failure (vol 16, pg 2561, 2015)
Araki, K.
Ishid, N.
Horii, R.
Takahashi, S.
Akiyama, F.
Ito, Y.
Ohno, S.
EXPERT OPINION ON PHARMACOTHERAPY, 2015, 16 (17) : V - V
[26] Multicenter Observational Study of Fulvestrant 500 mg in Postmenopausal Japanese Women with Estrogen Receptor-Positive Advanced or Recurrent Breast Cancer after Prior Endocrine Treatment (SBCCSG29 Study)
Kimizuka, Kei
Inoue, Kenichi
Nagai, Shigenori E.
Saito, Tsuyoshi
Nakano, Satoko
Futsuhara, Kazushige
Yamada, Hirofumi
Kaneko, Shiori
Sakurai, Takashi
Hata, Satoshi
Kurosumil, Masafumi
JOURNAL OF NIPPON MEDICAL SCHOOL, 2019, 86 (03) : 165 - 171
[27] Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the TREnd trial
Galardi, Francesca
De Luca, Francesca
Biagioni, Chiara
Migliaccio, Ilenia
Curigliano, Giuseppe
Minisini, Alessandro M.
Bonechi, Martina
Moretti, Erica
Risi, Emanuela
McCartney, Amelia
Benelli, Matteo
Romagnoli, Dario
Cappadona, Silvia
Gabellini, Stefano
Guarducci, Cristina
Conti, Valerio
Biganzoli, Laura
Di Leo, Angelo
Malorni, Luca
BREAST CANCER RESEARCH, 2021, 23 (01)
[28] Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the TREnd trial
Francesca Galardi
Francesca De Luca
Chiara Biagioni
Ilenia Migliaccio
Giuseppe Curigliano
Alessandro M. Minisini
Martina Bonechi
Erica Moretti
Emanuela Risi
Amelia McCartney
Matteo Benelli
Dario Romagnoli
Silvia Cappadona
Stefano Gabellini
Cristina Guarducci
Valerio Conti
Laura Biganzoli
Angelo Di Leo
Luca Malorni
Breast Cancer Research, 23
[29] DOLAF: An international multicenter phase II trial of durvalumab (MEDI4736) plus olaparib plus fulvestrant in patients with metastatic or locally advanced ER-positive, HER2-negative breast cancer selected using criteria that predict sensitivity to olaparib
Guiu Lahaye, Severine
Balmana Gelpi, Judith
Gauthier, Ludovic
Bigot, Frederic
Goncalves, Anthony
Frenel, Jean-Sebastien
Bachelot, Thomas
Dalenc, Florence
Mailliez, Audrey
Chakiba, Camille
Genet, Dominique
Dohollou, Nathalie
Desmoulins, Isabelle
Re Canon, Jean-Luc
Guyonneau, Clara
Buisson, Adrien
Chevalier, Louise-Marie
Delaloge, Suzette
Follana, Philippe
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[30] Next generation sequencing shows clonal selection after treatment with anastrozole or fulvestrant in a randomized trial of postmenopausal patients with large operable or locally-advanced hormone-receptor-positive breast cancer
Iggo, R. D.
Wood, H. M.
Rabbitts, P.
Quenel-Tueux, N.
Mauriac, L.
MacGrogan, G.
Bonnefoi, H.
CANCER RESEARCH, 2013, 73

← 1 2 3 4 5 →